384 related articles for article (PubMed ID: 25626317)
1. [The epigenetic alteration and the effect of HDAC inhibitors in multiple myeloma].
Terui Y
Nihon Rinsho; 2015 Jan; 73(1):124-9. PubMed ID: 25626317
[TBL] [Abstract][Full Text] [Related]
2. The potential role of epigenetic therapy in multiple myeloma.
Smith EM; Boyd K; Davies FE
Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
[TBL] [Abstract][Full Text] [Related]
3. In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
Maes K; De Smedt E; Kassambara A; Hose D; Seckinger A; Van Valckenborgh E; Menu E; Klein B; Vanderkerken K; Moreaux J; De Bruyne E
Oncotarget; 2015 Feb; 6(5):3319-34. PubMed ID: 25669970
[TBL] [Abstract][Full Text] [Related]
4. The biological significance of histone modifiers in multiple myeloma: clinical applications.
Ohguchi H; Hideshima T; Anderson KC
Blood Cancer J; 2018 Aug; 8(9):83. PubMed ID: 30190472
[TBL] [Abstract][Full Text] [Related]
5. Effects of epigenetic-based anti-cancer drugs in leukaemia and multiple myeloma cells.
Jugová A; Sustáčková G; Legartová S; Stixová L; Kozubek S; Bártová E
Cell Biol Int; 2011 Dec; 35(12):1195-203. PubMed ID: 21635225
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation.
Amodio N; D'Aquila P; Passarino G; Tassone P; Bellizzi D
Expert Opin Ther Targets; 2017 Jan; 21(1):91-101. PubMed ID: 27892767
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic modifications in prostate cancer.
Ngollo M; Dagdemir A; Karsli-Ceppioglu S; Judes G; Pajon A; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon DJ
Epigenomics; 2014; 6(4):415-26. PubMed ID: 25333850
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulatory mutations and epigenetic therapy for multiple myeloma.
Dupéré-Richer D; Licht JD
Curr Opin Hematol; 2017 Jul; 24(4):336-344. PubMed ID: 28441149
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic Activity of Peroxisome Proliferator-Activated Receptor Gamma Agonists Increases the Anticancer Effect of Histone Deacetylase Inhibitors on Multiple Myeloma Cells.
Aouali N; Broukou A; Bosseler M; Keunen O; Schlesser V; Janji B; Palissot V; Stordeur P; Berchem G
PLoS One; 2015; 10(6):e0130339. PubMed ID: 26091518
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer.
Sharma A; Heuck CJ; Fazzari MJ; Mehta J; Singhal S; Greally JM; Verma A
Wiley Interdiscip Rev Syst Biol Med; 2010; 2(6):654-69. PubMed ID: 20890963
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic mechanisms in AML - a target for therapy.
Oki Y; Issa JP
Cancer Treat Res; 2010; 145():19-40. PubMed ID: 20306243
[TBL] [Abstract][Full Text] [Related]
12. Panobinostat for the treatment of multiple myeloma.
Neri P; Bahlis NJ; Lonial S
Expert Opin Investig Drugs; 2012 May; 21(5):733-47. PubMed ID: 22404247
[TBL] [Abstract][Full Text] [Related]
13. Panobinostat, a pan-histone deacetylase inhibitor: rationale for and application to treatment of multiple myeloma.
Cheng T; Grasse L; Shah J; Chandra J
Drugs Today (Barc); 2015 Aug; 51(8):491-504. PubMed ID: 26380387
[TBL] [Abstract][Full Text] [Related]
14. [Development of novel epigenetic molecular-targeting agents].
Sowa Y; Sakai T
Nihon Rinsho; 2015 Aug; 73(8):1263-7. PubMed ID: 26281676
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic cancer therapy: Proof of concept and remaining challenges.
Mund C; Lyko F
Bioessays; 2010 Nov; 32(11):949-57. PubMed ID: 21154865
[TBL] [Abstract][Full Text] [Related]
16. DNA demethylating agents and epigenetic therapy of cancer.
Mani S; Herceg Z
Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
[TBL] [Abstract][Full Text] [Related]
17. Analysis of methylation pattern in multiple myeloma.
San-Miguel J; García-Sanz R; López-Pérez R
Acta Haematol; 2005; 114 Suppl 1():23-6. PubMed ID: 16166769
[TBL] [Abstract][Full Text] [Related]
18. Treatment of cardiovascular pathology with epigenetically active agents: Focus on natural and synthetic inhibitors of DNA methylation and histone deacetylation.
Chistiakov DA; Orekhov AN; Bobryshev YV
Int J Cardiol; 2017 Jan; 227():66-82. PubMed ID: 27852009
[TBL] [Abstract][Full Text] [Related]
19. Review-Epigenetic therapy for cancer.
Saleem M; Abbas K; Manan M; Ijaz H; Ahmed B; Ali M; Hanif M; Farooqi AA; Qadir MI
Pak J Pharm Sci; 2015 May; 28(3):1023-32. PubMed ID: 26004710
[TBL] [Abstract][Full Text] [Related]
20. The role of epigenetics in the biology of multiple myeloma.
Dimopoulos K; Gimsing P; Grønbæk K
Blood Cancer J; 2014 May; 4(5):e207. PubMed ID: 24786391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]